Quintrio
Home

Stock overview

PolyPid Ltd. Ordinary Shares

PYPD

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.

Last trade $6.40
Day change +$0.25 (+4.07%)
Day range $6.08 – $6.55
Volume 701,665
Market cap $130M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for PYPD.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for PYPD.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026

PolyPid announced results from a pooled microbiology analysis of three randomized trials (N=2,185) showing that D-PLEX₁₀₀ demonstrated lower bacterial burden in breakthrough surgical-site infections (16% vs 27% heavy bacterial growth, p=0.034) and delayed SSI onset compared to standard of care, without selecting for multidrug-resistant organisms. The findings support D-PLEX₁₀₀'s 60% relative risk reduction in SSI prevention demonstrated in the Phase 3 SHIELD II trial.

GlobeNewswire Inc.

PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

PolyPid Ltd., a late-stage biopharma company, announced it will report Q4 2025 financial results on February 11, 2026. The company expects to submit its New Drug Application (NDA) for D-PLEX100, its lead product candidate for preventing abdominal colorectal surgical site infections, in early 2026 following positive phase 3 results. A conference call and webcast will be held at 8:30 AM ET on the same day.

GlobeNewswire Inc.

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

PolyPid, a late-stage biopharma company, announced successful results from its Phase 3 SHIELD II trial for its lead product candidate D-PLEX100, which demonstrated a statistically significant reduction in surgical site infections. The company has secured additional funding of $26.7 million through the exercise of warrants, which is expected to extend its runway beyond the anticipated FDA approval of D-PLEX100.

GlobeNewswire Inc.

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

PolyPid, a late-stage biopharma company, announced that it will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11-12, 2025. The company's lead product candidate, D-PLEX100, is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Sep 21, 20231-for-30reverse split